Coalition for Epidemic Preparedness Innovations

Global COVID-19 Competitive Landscape Report 2023: Comprehensive Insights on 400+ Companies and 500+ Drugs - ResearchAndMarkets.com

Retrieved on: 
Monday, October 16, 2023
Infectious Diseases, Health, COVID-19, Shenzhen Stock Exchange, Respiratory failure, Acquisition, Report, Arcturus, Therapy, Coalition for Epidemic Preparedness Innovations, University, Safety, CEPI, Medication, AstraZeneca, Ageing, Siemens Healthineers, Vingroup, Developing country, Competitive landscape, Nanocovax, SARS-CoV-2, Epidemic, Coalition, Patient, Pharmaceutical industry, Vaccine

This "COVID-19 Competitive landscape 2023" report provides comprehensive insights about 400+ companies and 500+ drugs in COVID-19 Competitive landscape.

Key Points: 
  • This "COVID-19 Competitive landscape 2023" report provides comprehensive insights about 400+ companies and 500+ drugs in COVID-19 Competitive landscape.
  • The Report provides in-depth commercial assessment of drugs that have been included, which comprises collaboration, agreement, licensing and acquisition - deals values trends.
  • The sub-segmentation is described in the report which provide company-company collaboration (licensing/partnering), company academic collaboration and acquisition analysis in tabulated form.
  • Furthermore, the report delves into the development stages of emerging drugs, highlighting those in mid-stage and late-stage development, which are promising candidates for COVID-19 treatment.

IQVIA and CEPI Collaborate to Strengthen Global Research Preparedness to Advance the 100 Days Mission

Retrieved on: 
Wednesday, October 11, 2023
COVID-19, Infectious Diseases, Clinical Trials, Health Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Disease, Infection, NYSE, Global Public Health (journal), Research, Vaccine, IQV, Surge (drink), CEPI, Pandemic, G7, G20, Developing country, Epidemic, Low, Coalition for Epidemic Preparedness Innovations, Coalition, Patient, Pharmaceutical industry, IQVIA

IQVIA, (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations (CEPI) today announced a strategic collaboration to advance the 100 Days Mission.

Key Points: 
  • IQVIA, (NYSE:IQV), a leading global provider of advanced analytics, technology solutions, and clinical research services, and The Coalition for Epidemic Preparedness Innovations (CEPI) today announced a strategic collaboration to advance the 100 Days Mission.
  • In conjunction with national and regional collaborators, CEPI and IQVIA will aim to enhance the world’s preparedness to rapidly conduct life-saving clinical research for vaccines and other biological countermeasures against emerging infectious diseases.
  • This clinical research preparedness has been identified as a key enabler of the 100 Days Mission : a goal spearheaded by CEPI, and backed by the G7 and G20, which aims to accelerate the time taken to develop safe, effective, globally accessible vaccines against emerging disease outbreaks to within 100 days.
  • IQVIA’s collaboration with CEPI will support the 100 Days Mission in delivering transformative healthcare worldwide.

BioNTech and CEPI Announce Partnership to Advance mRNA Mpox Vaccine Development and Support CEPI’s 100 Days Mission

Retrieved on: 
Monday, September 18, 2023
Vaccine, Epidemic, BioNTech, Partnership, Vaccination, Public, Coalition, CEPI, Infection, Clinical trial, Malaria, Coalition for Epidemic Preparedness Innovations, Smallpox, History, Messenger, G7, MPXV, Monkeypox virus, Mpox, BNTX, G20, Knowledge, Pregnancy, Immunodeficiency, Virus, Safety, Tuberculosis, Orthopoxvirus

Since the eradication of smallpox in 1980, the global population-level immunity against the Orthopoxvirus viral family, including mpox, has been waning3.

Key Points: 
  • Since the eradication of smallpox in 1980, the global population-level immunity against the Orthopoxvirus viral family, including mpox, has been waning3.
  • BioNTech is aiming to develop a prophylactic mRNA-based mpox vaccine with a favorable safety profile that can be manufactured at scale.
  • The partnership between BioNTech and CEPI could help accelerate responses to future outbreaks caused by viruses of the Orthopoxvirus viral family in several ways.
  • BioNTech and CEPI are committed to enabling equitable access to the outputs of this partnership.

Health Canada Accepts Valneva’s Chikungunya Vaccine License Application for Review

Retrieved on: 
Tuesday, August 29, 2023
Epidemic, Priority review, NDS, Biologics license application, Pan American Health Organization, Saint-Herblain, Priority, Marketing, Coalition, European Medicines Agency, Valneva SE, CEPI, PAHO, Coalition for Epidemic Preparedness Innovations, Licensure, Chikungunya, Person, Trial of the century, Fast track (FDA), EMA, Euronext Paris, VLA, MD, Instituto Butantan, Ageing, FDA, Health Canada, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Pharmaceutical industry, Vaccine, Lancet

Based on Health Canada’s performance standard to process an NDS application, the Company believes the regulatory review could be completed by mid-2024.

Key Points: 
  • Based on Health Canada’s performance standard to process an NDS application, the Company believes the regulatory review could be completed by mid-2024.
  • This is the second regulatory application for VLA1553 filed by Valneva, and the Company intends to make additional regulatory submissions in 2023.
  • A Biologic License Application (BLA) is currently under priority review1 by the U.S. Food and Drug Administration (FDA)2.
  • VLA1553 is currently the only chikungunya vaccine candidate worldwide for which regulatory review processes are underway and, if approved, it could become the first licensed chikungunya vaccine available to address this unmet medical need.

Valneva Reports Positive Initial Phase 3 Safety Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate

Retrieved on: 
Monday, August 28, 2023
Epidemic, Biologics license application, DSMB, Saint-Herblain, Coalition, European Medicines Agency, Valneva SE, CEPI, Clinical trial, Coalition for Epidemic Preparedness Innovations, Licensure, Prescription Drug User Fee Act, EMA, Euronext Paris, Food and Drug Administration Amendments Act of 2007, VLA, Instituto Butantan, PDUFA, Adolescence, Ageing, FDA, Lancet, BLA, Food, Safety, CHIKV, Vaccine, Pharmaceutical industry, Chikungunya

Saint-Herblain (France), August 28, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus (CHIKV) vaccine candidate VLA1553.

Key Points: 
  • Saint-Herblain (France), August 28, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus (CHIKV) vaccine candidate VLA1553.
  • An independent DSMB has continuously evaluated safety data during the trial and has not identified any safety concerns.
  • Importantly, the initial data suggest a favorable safety profile in seropositive participants, confirming the observations following re-vaccination of individuals in Phase 1 trial VLA1553-1011.
  • If approved, VLA1553 could become the first licensed chikungunya vaccine available to address this unmet medical need.

Needle-free vaccine delivery platform aims to end frozen storage needs and improve access

Retrieved on: 
Tuesday, June 6, 2023
Vaccine, Epidemic, Heart, Partnership, Vaccination, Public, Coalition, CEPI, COVID-19, Coalition for Epidemic Preparedness Innovations, Light, Messenger, LMIC, Protein, Developing country, Policy, Pharmaceutical industry

OSLO, Norway and OXFORD, United Kingdom, June 06, 2023 (GLOBE NEWSWIRE) -- CEPI, the Coalition for Epidemic Preparedness Innovations, and aVaxziPen Ltd, a biotech company developing a novel needle-free vaccine delivery platform, have today announced a partnership to advance the development of two vaccines candidates (one protein and one mRNA-based) using aVaxziPen’s solid dose vaccine-delivery platform, which could help end the need for frozen storage of vaccines, thereby improving equitable access to vaccines. CEPI will initially provide up to US$1.6 million to establish proof-of-concept for aVaxziPen’s vaccine-delivery technology by evaluating stability, delivery and preclinical immunogenicity of both mRNA and protein-based vaccines developed using aVaxziPen’s platform.

Key Points: 
  • The current generation of mRNA vaccines require frozen storage due to the fragility of mRNA molecules.
  • Removing the need for frozen storage would make mRNA vaccines significantly easier, and cheaper, to ship, store and distribute in low-resource settings.
  • aVaxziPen’s innovative vaccine delivery technology requires little-to-no training to administer, while simultaneously reducing the need for expensive and burdensome cold-chain storage, allowing for easier distribution and administration.
  • This is a great step forward in our mission to disrupt the vaccine market, providing improved vaccine coverage around the world, reaching under-served populations and markets.”

Valneva Files for Chikungunya Vaccine Authorization with Health Canada

Retrieved on: 
Tuesday, May 30, 2023
Epidemic, Biologics license application, Pan American Health Organization, Saint-Herblain, Vaccination, Priority, Coalition, European Medicines Agency, Valneva SE, CEPI, PAHO, Coalition for Epidemic Preparedness Innovations, Licensure, Chikungunya, Person, Trial of the century, Fast track (FDA), EMA, Euronext Paris, VLA, MD, Instituto Butantan, PDUFA, Ageing, FDA, Health Canada, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BLA, Food, Pharmaceutical industry, Vaccine

Saint-Herblain (France), May 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the filing of a regulatory application with Health Canada for marketing approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553, in persons aged 18 years and above.

Key Points: 
  • Saint-Herblain (France), May 30, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announces the filing of a regulatory application with Health Canada for marketing approval of the Company’s single-shot chikungunya vaccine candidate, VLA1553, in persons aged 18 years and above.
  • If accepted, Health Canada will provide additional information on the potential approval timeline.
  • This is the second regulatory application for VLA1553 filed by Valneva, and the Company intends to make additional regulatory submissions in 2023.
  • VLA1553 is currently the only chikungunya vaccine candidate worldwide for which regulatory review processes are underway and, if approved, it could become the first licensed chikungunya vaccine available to address this unmet medical need.

Global Red Biotechnology Market to 2030: Declining Prices of DNA Sequencing Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 31, 2023
Biotechnology, Pharmaceutical, Health, Vaccine, Epidemic, Coalition for Epidemic Preparedness Innovations, Prevalence, Diabetes, Coalition, Enzyme, Cancer, DSM-IV codes, Antibody, USD, Incidence, Machine learning, Bharat Biotech, Artificial intelligence, Conditional sentence, Growth, A-DNA, Fine chemical

Robust pipeline is also expected to propel the growth of red biotechnology market on account of number of expected regulatory approvals in coming years.

Key Points: 
  • Robust pipeline is also expected to propel the growth of red biotechnology market on account of number of expected regulatory approvals in coming years.
  • COVID- 19 pandemic also had a positive impact on the global market.
  • By product, the monoclonal antibody is considered to be a relatively more mature and dominant segment compared to other products in the red biotechnology market.
  • By end-user, the pharmaceutical & biotechnology companies accounted for majority of revenue in the red biotechnology industry.

SK bioscience Presents Solution for Equitable Access of Vaccine at Regionalized Vaccine Manufacturing Collaborative of World Economic Forum

Retrieved on: 
Tuesday, May 23, 2023
Epidemic, Coalition for Epidemic Preparedness Innovations, Pan American Health Organization, SK, Multilateralism, WEF, Glocalization, Coalition, PAHO, CEPI, World Health Assembly, COVID-19, GAVI, African Center for Economic Transformation, Messenger, RVMC, Rochester Regional Health, Gavi, WHO, Vaccine, Ahn, World Health Organization, Pharmaceutical industry, Security (finance), Immunization, Health

Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event.

Key Points: 
  • Jaeyong Ahn, CEO of SK bioscience, presents the 'Glocalization' project to secure the global vaccine accessibility, claiming the importance of international cooperation to establish a regional-based vaccine hub at the Regionalized Vaccine Manufacturing Collaborative Side Event.
  • The RVMC is a global initiative launched at the World Economic Forum (WEF) in May 2022 to address inequality in vaccine distribution between few rich countries and low- and middle-income countries during the COVID-19 pandemic.
  • SK bioscience came up with a regional-based vaccine hub as a business model during the COVID-19 pandemic when inequality in COVID-19 vaccine distribution was exposed.
  • Currently, SK bioscience is preparing to establish the regional vaccine hubs in the Middle East, Africa, Southeast Asia, and Latin America.

Gritstone bio Reports First Quarter 2023 Financial Results and Provides Corporate Updates

Retrieved on: 
Thursday, May 11, 2023
KRAS, SIV, Coalition, National Institute of Allergy and Infectious Diseases, Survival, RECIST, Congress, Lance, Patient, SLATE, Collaboration, Infection, Vaccination, Gritstone bio, National Cancer Institute, Research, Melinda French Gates, Lung cancer, ECCMID, Bill, CORAL, Conference, Vaccine, DNA, Gilead Sciences, Simian immunodeficiency virus, ESMO, CEPI, African, NSCLC, NAB, Immunotherapy, Messenger, CROI, Bill & Melinda Gates Foundation, European, NIAID, Epidemic, Circulating tumor DNA, CRC, HIV, Progression-free survival, SARS-CoV-2, Clinical trial, Coalition for Epidemic Preparedness Innovations, ChAdOx1, Fungal infection, Cryptocurrency, Pharmaceutical industry, Gritstone

EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate and clinical updates.

Key Points: 
  • We recently observed durable neutralizing antibody titers at 6 months following samRNA vaccination in over 100 vaccine-naïve subjects treated within our CORAL-CEPI trial, where interim results were presented at ECCMID 2023.
  • As of May 10, 2023, the company had randomized 71 of the initially planned 80 total patients.
  • Both datasets were presented at the 33rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2023).
  • In February 2023, results from a preclinical study conducted in collaboration with Gilead were presented at Conference on Retroviruses and Opportunistic Infections (CROI) 2023.